STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) — Abbott Cooper PLLC is investigating Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”) on behalf of the Company’s investors.
The investigation seeks to determine whether Seres’s board of directors (the “Board”) has violated its fiduciary duty by instituting measures intended to interfere with the ability of Seres’ stockholders to hold the Board accountable for Seres’ recent financial and stock price performance.
Seres stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing ac@abbottlawyer.com or visiting our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.
Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy. For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com.
CONTACT:
Abbott Cooper PLLC
Abbott Cooper
(475) 333-0674
www.abbottlawyer.com
Attorney advertising. Prior results do not guarantee a similar outcome.
- Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS - April 23, 2025
- BE Semiconductor Industries N.V. Announces Q1-25 Results - April 23, 2025
- JLT Mobile Computers renews its five-year agreement with Kaleris to continuously validate their computers for major releases of the N4 Terminal Operating System - April 23, 2025
